Catherine Skari

TIF At The NORBS Online Regional Conference For Rare Diseases – 23 0ctober 2020

Supporting Serbia and other Eastern European countries in their efforts to upgrade holistic care services for patients with rare diseases,…

Read More »

Hidden Victims Of The Pandemic: Blood Bank Stocks Run Low As India’s Healthcare System Buckles

As public healthcare resources are redirected to halt the spread of coronavirus, victims of other life-threatening diseases pay the ultimate…

Read More »

New Video Series on Living With Thalassaemia by CDC & CAF

Read More »

Fulcrum Therapeutics to Initiate Phase 1 Trial with FTX-6058 for Sickle Cell Disease

Fulcrum Therapeutics, Inc.  a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced…

Read More »

TIF Develops Mobile Application To Support Patients With Thalassaemia

As part of its enduring efforts to develop useful tools for individuals with thalassaemia and haemoglobin disorders worldwide, TIF will…

Read More »

Coming Up This Week: ”Iron Monitoring in Thalassaemia” Webinar for Patients

Although chronic blood transfusion regimens have added decades to the lives of patients with thalassaemia, clinicians are now faced with…

Read More »

Pancyprian Thalassaemia Conference 2020

Τhe Pancyprian Thalassaemia Conference 2020 was successfully held on Saturday, 26 September, to discuss the modern scientific and other developments…

Read More »

Gene Therapy LentiGlobin Granted Priority Medicines Designation for Sickle Cell Disease in the EU

Bluebird Bio’s investigational gene therapy LentiGlobin has been granted priority medicines (PRIME) designation by the European Medicines Agency (EMA) for the treatment of sickle cell disease (SCD). Given to…

Read More »

Health Canada Approves REBLOZYL® For Adult Patients with β-Thalassaemia

Bristol Myers Squibb Canada (BMS) and Acceleron Pharma Inc. announced today that Health Canada has approved REBLOZYL® (luspatercept) for the treatment…

Read More »